Fig. 2From: Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in SpainMarkov model structure for children with CHD after the first year of the modelBack to article page